PHYSIOMICS PLC – Physiomics Awarded Multiple New Contracts
RNS Number : 4038L Physiomics PLC 08 July 2026 8 July 2026 Physiomics plc (“Physiomics” or the
RNS Number : 4038L Physiomics PLC 08 July 2026 8 July 2026 Physiomics plc (“Physiomics” or the
RNS Number : 4810K Physiomics PLC 01 July 2026 1 July 2026 Physiomics plc (“Physiomics” or the
RNS Number : 8827J Physiomics PLC 26 June 2026 26 June 2026 Physiomics plc (“Physiomics” or the
Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, today announces that its total income for the financial year ending 30 June 2021 is likely to be in the range of £700k-£800k and its loss after tax in the range of £170-200k.
Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, today announces its financial results for the six months ended 31 December 2019.
Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), today announces an update on trading for the half-year ended 30 June 2019.
Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm that is has successfully completed the Innovate UK grant project announced in March 2018.
The Board of Physiomics Plc, a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry (AIM: PYC), today announces its financial results for the six months ended 31 December 2018.